PharmaCielo Ltd. (TSXV:PCLO)
Canada
· Delayed Price · Currency is CAD 0.0650
+0.0100 (18.18%)
Mar 9, 2026, 10:00 AM EST
PharmaCielo Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1.75 | 3.17 | 3.48 | 1.54 | 5.31 | 1.94 | Upgrade
|
| Revenue Growth (YoY) | -49.67% | -8.81% | 125.70% | -70.96% | 172.93% | -26.71% | Upgrade
|
| Cost of Revenue | 2.06 | 2.8 | 2.75 | 2.91 | 4.27 | 6.12 | Upgrade
|
| Gross Profit | -0.31 | 0.37 | 0.73 | -1.37 | 1.04 | -4.17 | Upgrade
|
| Selling, General & Admin | 4.24 | 5.11 | 5.42 | 8.31 | 11.66 | 19.15 | Upgrade
|
| Other Operating Expenses | -1.11 | -0.21 | -0.24 | -0.09 | -0.15 | - | Upgrade
|
| Operating Expenses | 3.28 | 5.09 | 5.4 | 8.58 | 11.97 | 20.89 | Upgrade
|
| Operating Income | -3.59 | -4.72 | -4.67 | -9.95 | -10.93 | -25.06 | Upgrade
|
| Interest Expense | -2.41 | -3.19 | -2.26 | -2.69 | -1.54 | -0.2 | Upgrade
|
| Interest & Investment Income | - | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -1 | -0.47 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.5 | -0.08 | -0.1 | 0.09 | -0.12 | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.09 | -0.3 | -1.35 | 0.07 | 0.42 | -0.36 | Upgrade
|
| EBT Excluding Unusual Items | -7.58 | -8.29 | -8.37 | -12.48 | -13.15 | -26.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.19 | -0.19 | - | 0.03 | -0.14 | -0.43 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.91 | - | - | - | 0.04 | - | Upgrade
|
| Asset Writedown | 0.16 | -0.66 | -0.82 | -4.23 | -1.27 | - | Upgrade
|
| Other Unusual Items | 0.04 | 0.04 | 0.05 | 0.39 | - | - | Upgrade
|
| Pretax Income | -4.65 | -9.1 | -9.14 | -16.3 | -14.52 | -26.63 | Upgrade
|
| Net Income | -4.65 | -9.1 | -9.14 | -16.3 | -14.52 | -26.63 | Upgrade
|
| Net Income to Common | -4.65 | -9.1 | -9.14 | -16.3 | -14.52 | -26.63 | Upgrade
|
| Shares Outstanding (Basic) | 187 | 174 | 171 | 160 | 151 | 146 | Upgrade
|
| Shares Outstanding (Diluted) | 187 | 174 | 171 | 160 | 151 | 146 | Upgrade
|
| Shares Change (YoY) | 9.40% | 1.96% | 6.83% | 6.03% | 3.67% | 29.41% | Upgrade
|
| EPS (Basic) | -0.02 | -0.05 | -0.05 | -0.10 | -0.10 | -0.18 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.05 | -0.05 | -0.10 | -0.10 | -0.18 | Upgrade
|
| Free Cash Flow | -1.22 | -1.69 | -1.97 | -5.17 | -10.4 | -21.21 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.03 | -0.07 | -0.15 | Upgrade
|
| Gross Margin | -17.66% | 11.77% | 21.00% | -88.78% | 19.55% | -214.48% | Upgrade
|
| Operating Margin | -204.69% | -148.74% | -134.06% | -645.41% | -205.85% | -1288.29% | Upgrade
|
| Profit Margin | -265.70% | -286.63% | -262.70% | -1057.09% | -273.45% | -1369.14% | Upgrade
|
| Free Cash Flow Margin | -69.52% | -53.10% | -56.59% | -335.01% | -195.86% | -1090.55% | Upgrade
|
| EBITDA | -2.48 | -3.41 | -4.53 | -8.57 | -10.55 | -24.8 | Upgrade
|
| EBITDA Margin | -141.84% | -107.34% | -130.12% | - | -198.76% | - | Upgrade
|
| D&A For EBITDA | 1.1 | 1.31 | 0.14 | 1.38 | 0.38 | 0.26 | Upgrade
|
| EBIT | -3.59 | -4.72 | -4.67 | -9.95 | -10.93 | -25.06 | Upgrade
|
| EBIT Margin | -204.69% | -148.74% | -134.06% | - | -205.85% | - | Upgrade
|
| Revenue as Reported | 1.75 | 3.17 | 3.48 | 1.54 | 5.31 | 1.94 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.